Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar bruceedge (< 20) Submitted: 6/19/2011 2:15:36 PM : Outperform Start Price: $2.57 DVAX Score: +37.31

good pipeline in the works and a good technical chart cupping around it's 200 day M.A.

Featured Broker Partners


Advertisement